House Republicans’ $1.51 trillion tax reform bill released Thursday would repeal the orphan drug tax credit, which currently allows drug manufacturers to claim a credit equal to 50 percent of the costs of any human clinical testing done for a product in a rare disease, as defined by the FD&C Act.
Source: Drug Industry Daily